Sara Zemiti

Sara Zemiti

Auto-generated profile, based on publicly available information

Sara Zemiti

IRMB, University of Montpellier, INSERM, CHU Montpellier, Montpellier, France

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
RHRawan Hallal
Rawan Hallal
MTMarion de Toledo
Marion de Toledo
DTDenis Tempé
Denis Tempé
RBRayane Berrahouane
Rayane Berrahouane
SZSara Zemiti
Sara Zemiti
GBGuillaume Bossis
Guillaume Bossis
NK cells can play a significant role in the antitumoral immune response. In patients with acute myeloid leukemia (AML), NK cells are, however, often found in low numbers and exhibit poor activity, contributing to leukemic progression. Allogenic NK cells are emerging as promising cellular therapies for hematologic cancer treatment. New strategies are however required to both reactivate NK cells in patients with AML and enhance the antitumor activity of transplanted NK cells. In this study, we demonstrate that targeting SUMOylation, a protein posttranslational modification, activates NK cells from both healthy donors and patients with AML. Subasumstat (TAK-981), a first-in-class inhibitor of SUMOylation used in phase I/II clinical trials, enhances NK cell degranulation, secretion of inflammatory cytokines (IFN-γ, TNF-α, and FasL), and cytotoxicity against AML cells. In vivo, TAK-981 improves the anti-leukemic efficacy of ex vivo expanded cord blood NK cells in leukemia-bearing mice. One early effect of TAK-981 is to specifically increase the accessibility and activation of cis-regulatory regions of IFN-I pathway genes and induce their transcription. TAK-981–induced secretion of IFN-β, mostly by NK cells and myeloid cells, is required for NK cell activation. Surprisingly, IFNB1 induction does not require its best-characterized activators MDA5, cGas, and IFN response factor-1, -3, and -7. Altogether, this suggests that targeting SUMOylation activates a noncanonical IFN-I pathway, which enhances the anti-leukemic potential of NK cells.

30 August 2025 in bioRxiv
Verified
Preprint
Open access
SZSara Zemiti
Sara Zemiti
SESteffy Escayg
Steffy Escayg
BHBenjamin Hay
Benjamin Hay
ABAmel Bouzid
Amel Bouzid
CACatherine Alexia
Catherine Alexia
DGDelphine Gitenay
Delphine Gitenay
Metastasis is largely controlled by Natural Killer (NK) cell-mediated immune surveillance. To colonize new environments, cancer cells undergo epithelial to mesenchymal transition (EMT), which allows them to detach and migrate. EMT is fueled by fatty acid oxidation (FAO), which partially replaces glycolytic-based tumor metabolism. Whether metabolic rewiring affects the targeting of cancer cells by NK cells remains unknown. Here, we show that forcing solid cancer cells to perform FAO by inhibiting pyruvate dehydrogenase kinase 1 with dichloroacetate (DCA) activates extracellular signal-regulated kinase-5 (ERK5), triggering EMT and tumor cell migration and invasion. Concomitantly, FAO induces the expression of ligands that mediate NK cell recognition. Consequently, NK cells better infiltrated DCA-treated 3D tumor spheroids, where they exerted their cytotoxic effects. DCA-treated cells showed increased migration in a zebrafish model, whereas metastasis from mammary cancer cells grafted into immune-deficient mice was enhanced by DCA. These migrating/metastatic cells are preferentially killed by NK cells, which strongly limit their invasive potential. Hence, FAO promotes both metastasis and NK-mediated tumor surveillance, highlighting the Achilles’ heel of metastatic cells, which may offer new therapeutic opportunities. Teaser: Metastasis recognition and killing by immune cells, such as NK cells, requires a metabolic shift that relies on lipid metabolism.

2 January 2026
Verified
Other
Open access
RHRawan Hallal
Rawan Hallal
MTMarion de Toledo
Marion de Toledo
DTDenis Tempé
Denis Tempé
RBRayane Berrahouane
Rayane Berrahouane
SZSara Zemiti
Sara Zemiti
GBGuillaume Bossis
Guillaume Bossis
Supplementary Table S1 provides information on the antibodies used for flow cytometry

2 January 2026
Verified
Other
Open access
RHRawan Hallal
Rawan Hallal
MTMarion de Toledo
Marion de Toledo
DTDenis Tempé
Denis Tempé
RBRayane Berrahouane
Rayane Berrahouane
SZSara Zemiti
Sara Zemiti
GBGuillaume Bossis
Guillaume Bossis
Supplementary Table S4 provides the sequence of the gRNA used to knock out MDA5, IRF1, IRF3, IRF7 in THP1 cells

2 January 2026
Verified
Other
Open access
RHRawan Hallal
Rawan Hallal
MTMarion de Toledo
Marion de Toledo
DTDenis Tempé
Denis Tempé
RBRayane Berrahouane
Rayane Berrahouane
SZSara Zemiti
Sara Zemiti
GBGuillaume Bossis
Guillaume Bossis
Supplementary Table S5 provides the raw data for live cell cytotoxicity experiments using Incucyte

2 January 2026
Verified
Other
Open access
RHRawan Hallal
Rawan Hallal
MTMarion de Toledo
Marion de Toledo
DTDenis Tempé
Denis Tempé
RBRayane Berrahouane
Rayane Berrahouane
SZSara Zemiti
Sara Zemiti
GBGuillaume Bossis
Guillaume Bossis
Supplementary Figure S2 shows that SUMOylation regulates IFN-I pathway genes enhancers activity and accessibility